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of malignant disease relies on the specificity and association
constant of single-chain variable fragments (scFvs). The latter
are synthesized from parent antibodies by fusing their light
(VL) and heavy (VH)-chain variable domains into a single chain
using a flexible linker peptide. The fusion of VL and VH do-
mains can distort their relative orientation, thereby compro-
mising specificity and association constant of scFv, and
reducing the lytic efficacy of CAR-T cells. Here, we circumvent
the complications of domains’ fusion by designing scFv mu-
tants that stabilize interaction between scFv and its target,
thereby rescuing scFv efficacy. We employ an iterative
approach, based on structural modeling and mutagenesis
driven by computational protein design. To demonstrate the
power of this approach, we use the scFv derived from an anti-
body specific to a human leukocyte antigen A2 (HLA-A2)-
HER2-derived peptide complex.Whereas the parental antibody
is highly specific to its target, the scFv showed reduced speci-
ficity. Using our approach, we design mutations into scFvs
that restore specificity of the original antibody.Received 1 August 2019; accepted 24 August 2019;
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Single-chain variable fragments (scFvs), obtained from antibodies by
connecting their light (VL) and heavy (VH)-chain domains with a
peptide flexible linker, allow harnessing specificity of antibodies in
a conceptually simpler single-chain construct. scFvs are generally
used in phage display,1 flow cytometry, immunohistochemistry,
and more recently, in generating chimeric antigen receptors (CARs)
in which the scFv is fused with T cell signaling molecules to redirect
the antigen specificity of T lymphocytes.2,3 Despite successful applica-
tions of scFv in CAR-T, the specificity and the association constant of
the scFvs do not always match those of the parent antibody, because
rewiring the connectivity of VL and VH chain domains of the parent
antibody can change their dynamics and relative orientation.
To demonstrate this complication in constructing scFv, we selected an
antibody that recognizes a peptide processed and presented physiolog-30 Molecular Therapy: Oncolytics Vol. 15 December 2019 ª 2019 The
This is an open access article under the CC BY-NC-ND license (http:ically into the grove of the human leukocyte antigenA2 (HLA-A2) com-
plex, reasoning that even small distortions of the antibody structure in a
scFv format may alter the recognition of the peptide/HLA complex
because of the high specificity of the peptide/HLA interaction. We
developed an antibody (SF2) specific to the HLA-A2/peptide complex
in which the KIFGSLAFL peptide derives from the human HER2 pro-
tein. The SF2 antibody shows no binding toward the empty HLA-A2
complex, whereas the binding to the HLA-A2/KIFGSLAFL peptide
complex is typically peptide concentration dependent (Figure S1). We
then cloned the VH and VL chains of the SF2 antibody and generated
a scFv by connecting the C terminus of VL with the N terminus of VH
via a Gly-Ser linker. This scFv was then fused with the hinge and trans-
membrane domain of CD8a and endodomains of CD28 and CD3z to
generate the CAR (SF2.CAR) (Figure S2A). Retroviral particles encod-
ing the SF2.CAR were used to generate SF2.CAR-expressing T cells
(SF2.CAR-Ts) using previously validated protocols to generate
CAR-T cells for clinical use (Figures S2B and S2C).4 Surprisingly,
SF2.CAR-T cells displayed activity not only toward T2 cells loaded
with the HER2 KIFGSLAFL peptide, but also against empty T2 cells
and T2 cells loaded with an irrelevant peptide as assessed by interferon
gamma (IFNg) release assay (Figure S2D), indicating that the scFv
conformation or its assembling in the CAR format substantially modify
the specificity of the parental SF2 antibody.
We argued that by mutating key residues in the binding interface be-
tween scFv and theHLA-A2/peptide complex, we can restore specificity
of scFv toward the target HER2 peptide. This approach requires knowl-
edge of the complex tertiary structure. Traditional methods of tertiaryAuthors.
//creativecommons.org/licenses/by-nc-nd/4.0/).
A B Figure 1. The Root-Mean-Square Fluctuations
(RMSFs) of the scFv and the Antibody Backbones
(A and B) RMSF in (A) VL and (B) VH domains. Blue and red
lines correspond to RMSF values for the scFv and the
antibody, respectively.
www.moleculartherapy.orgstructure determination such as X-ray crystallography or cryo-electron
microscopy are technically challenging and provide only a static snap-
shot of the structure. NMR can be used to explore structure dynamics,
but protein size is a limiting factor for the NMR applicability. Compu-
tational modeling provides an alternative to experimental approaches
and allows to predict structure and explore its dynamics. However,
due to inaccuracies present in modern force fields, computational
modeling cannot unambiguously identify the correct structure but
can provide a range of alternative models. To validate the model of
scFv bound to the HLA-A2/peptide complex, we generated a set of
scFv mutants. We developed an empirical scoring function, which al-
lowed us to rank computational models based on comparison between
predicted and experimentally measured effects, which these mutants
exert on binding between scFv and the HLA-A2/peptide complex.
The top-rankedmodels were selected and evaluated using an additional
set of mutants. By following this iterative modeling and redesign pro-
cedure, we determined the structure of scFv complexed with HLA-A2
loaded with the HER-2 peptide, and identified mutations that improve
the binding specificity of the scFv in the CAR format.
RESULTS
Probing Structure of scFv Bound to the HLA-A2/KIFGSLAFL
Peptide Complex
The computational methods used for prediction of antibody structure
have gradually improved over the last decade as revealed by the Anti-
bodyModeling Assessment, a community-wide competition aimed to
evaluate performance of antibody modeling software.5,6 The best
models match experimental structures with angstrom accuracy even
for the hardest to predict, the third complementarity-determining re-
gion (CDR) of the VH variable domain.
7 To predict the tertiary struc-
ture of the SF2 antibody, we used antibody modeling software.8 The
corresponding scFv is obtained by connecting the C terminus of VL to
the N terminus of VH by (GGGGS)3 linker. To explore dynamics of
these structures, we ran discrete molecular dynamics (DMD)
simulations9–11 (Materials and Methods). We found that although
the mutual orientation of VL and VH is the same both in antibody
and scFv, scFv exhibits higher fluctuations, as revealed by the distri-
bution of root-mean-square fluctuations (RMSFs) (Figure 1; Videos
S1 and S2). Thus, increased flexibility of the scFv, as compared with
the SF2 antibody, affects specificity of the scFv. We argue that we
can restore the specificity of the scFv by introducing mutations that
stabilize it on substrate, thereby decreasing its flexibility.Molecular TWe used template structure (PDB: 1HHI)
to model HLA-A2/peptide (Materials and
Methods). To infer binding pose of scFv to
the HLA-A2/peptide complex, we used docking
software.12,13 After discarding apparentlyinconsistent models (Figure 2B), where none of the six comple-
mentarity-determining regions (CDRs) of the scFv binds the
HER2 peptide, we obtained 270 3D models. We then clustered
these models (Figure 2C) and identified eight distinct clusters (Fig-
ure S3). For each cluster we chose a centroid structure as a repre-
sentative model. For each residue within CDRs of representative
models, we considered all possible mutations and calculated: (1)
change in stability of the scFv/HLA-A2/peptide complex upon mu-
tation; (2) change in the interaction energy between scFv and pep-
tide; and (3) change in the interaction energy between scFv and
HLA-A2 (Materials and Methods). We selected a set of six muta-
tions in VH and six mutations in VL domains (named set I) for
further experimental probing. The selected mutations stabilize
the interaction between scFv and peptide relatively to the interac-
tion between the antibody and HLA-A2 complex in more than one
considered model.
We validated these mutations by generating mutant SF2.CAR mol-
ecules, constructing CAR-T cells for each specific mutant, and
testing their specific activity. For this purpose, we measured IFNg
release by CAR-T cells co-cultured with T2 cells loaded with
the specific HER2-P369–377 peptide or with the irrelevant
MAGEA3-P271–279 peptide or not loaded with any peptide
(Figure S4). The results showed that the mutations VL-S31Y,
VL-G93L, and VH-G55F did not affect the specific binding to
HER2-P369–377 peptide-loaded HLA-A2 molecules but decreased
the binding to irrelevant MAGEA3-P271–279 peptide-loaded HLA-
A2 molecules and to empty HLA-A2 molecules.
For each computational model we calculated the scoring function in
order to assess compatibility of the model and experimental data (Fig-
ure 2D) (Materials and Methods). The scoring function is a sum of
scores over all experimentally tested mutations and consists of two
terms. In the first term the theoretically calculated change in global
stability of the HLA-A2/peptide-antibody complex (DDGTH) is
compared with the approximate value derived from experimental
data (DDGEXP). In the second term the relative stabilization of inter-
action between scFv and peptide versus interaction between scFv and
HLA-A2 is calculated theoretically (DEpep-HLA-Ab
TH) and compared
with the approximate value derived from experimental data
(DEpep-HLA-Ab
EXP). The model with minimal score corresponds to




Figure 2. Structure Prediction Workflow
(A) Structural models are created for scFv and HLA-A2molecule loaded with HER2-
derived peptide. (B) Computation docking of scFv to the HLA-A2/peptide complex.
Models, where scFvs do not touch peptide, are discarded. (C) Clustering of derived
models. (D) Residues in the CDRs of scFvs are explored for the effect of their mu-
tations on the centroids of the clusters from step (C). (E) The models most
compatible with predictions are further selected and clustered with a smaller cutoff.
New mutations are proposed.
Molecular Therapy: OncolyticsIt is noteworthy that choice of initial mutations is not unique, and
alternative sets can be used instead. However, our choice of initial
set based on stabilization of antibody/peptide interaction in some
of the models allows us in case of success to obtain correct mutations
already with the first set of experiments. After ranking models using
our scoring function, we selected the top 10 models (out of 270 initial
models). For these models we selected a new set of best matching mu-
tations (named set II) that consists of sevenmutations in total. CAR-T
cells expressing these new SF2.CAR mutants were generated, and
their function was tested by the co-culture experiment and IFNg
release assay (Figure S5). We find that the mutations S53M and
S100V increased binding to HER2-P369–377 peptide-loaded HLA-A2
molecules but decreased the binding to irrelevant MAGEA3-
P271–279 peptide-loaded HLA-A2 molecules and to empty HLA-A2
molecules.
The functional characterization of the new scFv mutations of set II,
along with the best mutations from set I, was further validated with
CAR-T cells generated from multiple donors and illustrated in Fig-
ure 3. They were evaluated using our scoring function. Based on these
results, we selected the model with the lowest scoring function
(Figure 4A).32 Molecular Therapy: Oncolytics Vol. 15 December 2019Assessment of the Model Quality
The selected model correctly describes most of the mutations from
sets I and II. Three mutations from set I (VL S31Y, VL G93L, and
VH G55F) exhibited decrease in binding affinity to both empty and
peptide-loaded HLA-A2 complex (Figure S4). Based on our model,
we predict that upon these mutations, large hydrophobic residues
become exposed to the solvent (Figures 4B–4D), thus decreasing
overall stability of the complex. Two mutations from set II
(VH S100V and VH S53M) (Figures 4E and 4F) preserved binding af-
finity of the scFv to peptide-loaded HLA-A2, whereas drastically
reducing binding to the empty HLA-A2 complex (Figure S5). In
line with this observation, our model suggested that these residues
directly interact with F8 residue of the peptide, which provides an
anchor for successful recognition of the peptide by the scFv. These
mutations increase contact surface between F8 and the scFv, thus
increasing the energy of van der Waals interactions.
The developed structural model also explains differential effects of the
A50 mutations, such that A50L completely abrogates the interaction
between scFv and the HLA-A2 complex, whereas A50V conserves
some residual binding, and A50F preserves the binding but reduces
its specificity. According to our model, A50L and A50V mutations
result in clashes with the HLA-A2 H1 helix, whereas A50F mutation
rests on top of the H1 helix without clashes (Figure S6). Furthermore,
interaction between A50F mutation and H1 helix increases the bind-
ing between scFv and the empty HLA-A2 complex, causing reduced
specificity for the interaction with the peptide.
We also compared binding pose of the scFv as inferred from the
modeling to the orientation of typical T cell receptor (TCR) bound
to the HLA-A2/peptide complex (Figure S7). At least 50 unique
TCR-peptide-major histocompatibility complex (MHC) class I com-
plexes with 3D structures have been deposited into the PDB. All of
them follow the classical binding pattern of TCR14 with a few excep-
tions where TCR orientation is flipped by 180.15 A typical TCR binds
the MHC complex in the gap between H1 and H2 helices, thus maxi-
mizing interaction with a peptide and minimizing non-specific inter-
action with emptyMHC. The interaction with the peptide is mediated
by CDR3 loops, whereas germline-encoded CDR1 and CDR2 loops
mostly contact MHC H1 and H2 helices.14,16 In our model, scFv ac-
commodates a different binding pose. We observed that contact be-
tween scFv and peptide is mediated by H2 and H3 CDR loops. VL
does not bind the peptide but makes extensive contact to MHC walls.
This structure explains the high non-specific binding of the wild-
type scFv.
DISCUSSION
Here, we presented a novel approach for optimization of binding
specificity of scFv. It relies on structural modeling and mutagenesis,
and does not require prior knowledge of antibody 3D structure. We
validated our approach on the scFv derived from an antibody specific
to the KIFGSLAFL peptide loaded into the HLA-A2 complex. We
built a model of the complex that captures fine structural details,
such that it can explain the differences in binding of scFv to the
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Figure 3. IFNg Release by SF2.CAR Mutants
Control T cells (NTs), SF2.CAR-T cells, and T cells
expressing the CARs generated with the mutant scFvs
were cultured for 24 h with empty T2 cells or with T2
cells loaded with the KIFGSLAFL (HER2369–377) peptide or
an irrelevant peptide (MAGEA3271–279). All T cells
expressing the CAR were normalized for CAR expres-
sion. IFNg level released in the supernatant was measured
by ELISA in the supernatant harvested following a 24-h
incubation. The results are average ± SD of four
experiments.
www.moleculartherapy.orgHLA-A2/peptide complex when the same residue is mutated to
different amino acids.
We found that the scFv is more flexible than parental SF2 antibody.
We also predicted that binding pose of the scFv on the top of the
HLA-A2/peptide complex differs from what is expected based on
comparison with TCR binding. These two observations together
can explain non-specific binding observed for the wild-type scFv.
We established twomutations that reduce non-specific binding, while
preserving binding to peptide loaded to the HLA-A2 complex at the
same level.
An interesting avenue to explore is possible allosteric effects, which
mutations exhibit on binding interface between scFv and the HLA-
A2/peptide complex. The phenomenon of allostery, which refers to
the process when perturbation of one site within a macromolecule af-
fects another distant site, attracts broad attention.17–19 In particular,
loop regions are shown to be important for propagation of allosteric
effects,20 which suggests potential importance of CDR loops in allo-
steric modulation of antigen binding. It was previously shown that
mutations can trigger allosteric modulations of antibody21 and
scFv.22 To reveal allosteric effects within our system, we used the
AlloSigMA server23 (Materials and Methods). Interestingly, we found
changes in protein dynamics far away frommutation sites (Figure S8),
which reveals allosteric modulation of binding between scFv and the
HLA-A2/peptide complex.
In the current manuscript we use standard (GGGGS)3 linker to con-
nect VL and VH chain variable domains into scFv. Optimization of the
linker length and composition can be used to further improve speci-
ficity of scFv. It was previously shown that lengthening of (GGGGS)n
linker can increase activity of scFv toward corresponding antigen,24
whereas shortening of the linker can destabilize interaction of VL
and VH within a single scFv and leads to multimerization of scFv.
25
Although antibodies can be derived to bind peptide inserted into the
MHC complex, their sequence is not optimized for minimization
of non-specific binding to the MHC complex as it is in the case of
TCRs, which evolved complementarity to MHC during millionsof years of evolution. Optimizing antibody design using sequence
snippets of the a- and b-chains of TCRmay improve low non-specific
binding affinity of TCRs.
There is a significant demand of finding an efficient way to optimize
the affinity of the scFv in CAR molecules with the goal to select and
maintain high specificity for antigens expressed at high levels in tu-
mor cells, but also expressed at low levels in some normal tissues.
Our proposed computational model can also be adapted to tune the
affinity of the scFv to minimize on target but out of tumor activity.
MATERIALS AND METHODS
Structure Modeling and Model Selection Workflow
The 3D structure of the SF2 antibody was built using the Kotai web
server.8 In total, 21 models of antibody, which differ in the conforma-
tion of the third complementarity-determining regions of a VH
variable domain (CDR H3), are considered (Figure 2A). HLA-A2
structure is built based on the template structure (PDB: 1HHI), where
we replace the original peptide by the HER2 peptide. For that we kept
peptide backbone geometry intact and replaced corresponding side
chains.We verified that anchor residues (positions 2, 6, and 9)26 point
inward HLA-A2. The initial structure was run through short DMD
simulation to release inter-atomic clashes. The simulation was run
for 10,000 steps at T = 0.5 kcal/(mol,kB) with heat exchange coeffi-
cient = 10. The Andersen thermostat is used.27
DMD simulations for the RMSF plot were performed for 1 million
steps at T = 0.55 kcal/(mol kB) with heat exchange coefficient = 0.1.
In total, five trajectories for SF2 antibody and five trajectories for
the scFv form of the antibody were produced. RMSF is calculated
over carbon-alpha atoms of the protein backbones.
Docking was performed with the ClusPro13 web server, resulting in
598 models in total (Figure 2B). The structure used for docking con-
tains VH and VL variable domains without the Gly-Ser linker. After
discarding apparently incorrect models, where none of the
six complementarity-determining regions (CDRs) of antibodies
touch the HER2 peptide, we got 270 3D models. The resulting





Figure 4. Structural Model Best Matching Mutagenesis Data
(A) scFv bound to the HLA-A2/KIFGSLAFL peptide complex. Black boxes highlight
location of five residues, which increase specificity of scFv toward the target peptide
upon specific mutation. (A–F) The mutants (B) VL S31Y, (C) VL G93L, (D) VH G55F,
(E) VH S53M, and (F) VH S100V are shown. These mutations were performed at two
sets of experiments (set I and set II). VL is colored in light blue; VH is colored in
magenta. The mutated residues are colored in cyan.
Molecular Therapy: OncolyticsT = 0.5 kcal/(mol,kB), heat exchange coefficient = 10]. The models
were aligned in 3D space using the position of HLA-A2 and clustered
by root-mean-square deviation (RMSD) of carbon-alpha backbone
atoms of antibodies (Figure 2C), which gave eight distinct clusters
(Figure S3). Clustering cutoff distance is 9 Å. The clusters were
counted if the number of structures in the cluster is R10.
We identified CDRs using a previously described set of rules.28 For
each structure representing centroid of clusters and for each CDR res-
idue (61 residues in total) we determined the effect of every possible
mutation (Figure 2D). For that we calculate: (1) change of HLA-A2/
peptide-antibody complex stability upon the mutation (DDG); (2)
change of interaction energy between antibody and HLA-A2
(DEHLA-Ab); and (3) change of interaction energy between antibody
and peptide (DEpep-Ab). The change of stability is calculated using
Eris software package in the scanning mode.29,30 The interaction en-
ergies are calculated using a software toolkit based on DMD10 and
Medusa force field.31,32 For experimental testing we selected muta-
tions that stabilize interactions between antibody and peptide as
compared with the interaction between antibody and HLA-A2
(DDG < 1.5 and DEpep-Ab  DEHLA-Ab < 1).
The models are checked for consistency with experimental data. For












1 if x <  1
x if  1< x < 1
1 if x > 1
x =DDG=Ethresh and Ethresh = 4kcal=mol is an empirically derived
threshold. The mutations withDDG exceeding this threshold severely
affect protein stability.
DDGEXP =
1 if y <  1
y if y >  1
y = ðIFNgWTHLApep  IFNgMUTHLApepÞ=IFNgWTHLApep, where
IFNgWTHLApep and IFNg
MUT
HLApep define interferon gamma response
as measured by ELISA assay for the wild-type and mutated antibodies
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1 if w <  1
w if  1<w< 1




, where IFNgWTHLA and
IFNgMUTHLApep define interferon gamma response as measured by
ELISA assay for the wild-type and mutated antibodies against empty
HLA-A2.
The first term in Equation 1 evaluates the difference between
theoretical and experimentally observed changes in HLA-A2/
peptide-antibody complex stability upon mutation, and the second
term evaluates the difference between theoretical and experimentally
observed ability of mutation to stabilize interactions between anti-
body and peptide as compared with the interaction between antibody
and HLA-A2.
Evaluation of Allosteric Effects
To evaluate allosteric effects in the scFv/HLA-A2/peptide system,
we employed the AlloSigMA server.23 The effect of three muta-
tions (VL S31Y, VL G93L, and VH G55F) was calculated using
the “DOWN-mutated residue” option. This option defines the
loosen local contact network. We chose it to describe local
www.moleculartherapy.orgdestabilization, which results in decreased binding of scFv to irrel-
evant MAGEA3-P271–279 peptide-loaded HLA-A2 molecules and
to empty HLA-A2 molecules. The effect of mutations VH S100V
and VH S53M was calculated using the “UP-mutated residue” op-
tion. This option defines the stiffen local contact network. It was
chosen to describe local stabilization, which results in increased
binding of scFv to HER2-P369–377 peptide-loaded HLA-A2
molecules.
Cell Lines
T2 cells were purchased from American Type Culture Collection
(ATCC) and cultured in RPMI1640 medium (GIBCO) supplemented
with 10% FBS and 2 mM GlutaMAX. All cell lines were mycoplasma
free and validated by flow cytometry for surface markers and func-
tional readouts as needed.
Generation and Characterization of mAb SF2
The mAb SF1 is secreted by a hybridoma generated by fusing mouse
myeloma cells P3-X36-Ag8.653 with splenocytes from an 8-week-
old female BALB/c mouse immunized with HLA-A2 antigen
HER2/neu369–377 peptide complexes according to the following
schedule. Three days before priming, the 6-week-old female
BALB/c mouse was injected intramuscularly with 100 mg (per
mouse) of granulocyte-macrophage colony-stimulating factor
(GM-CSF) plasmid. Subsequently, the mouse was primed with
HLA-A2 antigen HER2/neu369–377 peptide complexes (50 mg) utiliz-
ing saponin, which can enhance both B cell and T cell response33 as
an adjuvant. Boosters were given at 2-week intervals for a total of 14
times. Four days following the last booster a mouse was sacrificed.
Splenocytes were harvested from the immunized mouse and fused
to mouse myeloma cells P3-X36-Ag8.653 at a ratio of 1:1 as previ-
ously described.34 Twenty 96-well, flat-bottom microtiter plates
(Corning, Corning, NY, USA) were seeded with 1.5–2  105 cells/
well. Growth of colonies was observed in all seeded wells.
Supernatants were screened in ELISA with HLA-A2 antigen
HER2/neu369–377 peptide complexes.
HLA-A2 antigen/MAGE-3271–279 peptide complexes and HLA-A2/
MART127–35 peptide complexes were used as specificity controls. In
the first screening, about 30 hybridomas displayed higher reactivity
with HLA-A2 antigen HER2/neu369–377 peptide complexes than
with the other complexes. In additional screenings, only the hybrid-
oma SF1 maintained its selected reactivity with HLA-A2 antigen
HER2/neu369–377 peptide complexes. The mAb SF1-stained T2 cells
pulsed with the HER2/neu369–377 peptide, but not with peptides
derived from other tumor antigens.35 On the other hand, the mAb
SF1 did not stain cell lines that expressed both HLA-A2 and
HER2/neu.
Plasmid Construction and Retrovirus Production
The variable regions of the VH and VL chains of the SF2 mAb were
cloned from the SF2 mouse hybridoma. The VL amino acid sequence
was: 1-DIQMTQSPASLSVSVGETVTITCRPSENIYSNLAWYQQK
QGKSPQLLVYAATHLADGVPSRFSGSGSGTQYSLKINSLQSEDFGTYYCQHFWGTPYTFGGGTKLEIK-107. CDRs as identified using
a previously described set of rules28 are underlined. The correspond-
ing residue ranges are CDR1 (residues 24–34), CDR2 (residues




identified using a previously described set of rules28 are underlined.
The corresponding residue ranges are CDR1 (residues 23–35),
CDR2 (residues 50–58), and CDR3 (residues 96–106).
The scFv was created by connecting the C terminus of VL with the N
terminus of VH using 15-residue peptide linker GGGGSGGG
GSGGGGS and then cloned into a previously validated CAR cassette
that includes the human CD8a hinge and transmembrane domain,
CD28 intracellular costimulatory domains, and CD3z intracellular
signaling domain.4 The SF2.CAR cassettes were cloned into the retro-
viral vector SFG. Mutations of the scFv were created by PCR and were
listed as follows: set 1: VL S31Y (CDR1), N32Y (CDR1),
A50L (CDR2), A50F (CDR2), T52Y (CDR2), G93L (CDR3); VH
S28Y (CDR1), T30E (CDR1), S31L (CDR1), G55F (CDR2), S56Y
(CDR2), S100M (CDR3); and set 2: VL N32Q (CDR1), A50V
(CDR2), G93I (CDR3), G93V (CDR3); VH S53M (CDR2), S100V
(CDR3), H101I (CDR3). Retroviral supernatants were prepared as
previously described.36
Transduction and Expansion of Human T Cells
Buffy coats from healthy donors were obtained through the Gulf
Coast Regional Blood Center, Houston, TX, USA. Peripheral blood
mononuclear cells (PBMCs) isolated with Lymphoprep density sepa-
ration (Fresenius Kabi Norge) were activated using 1 mg/mL anti-CD3
(Miltenyi Biotec) and 1 mg/mL anti-CD28 (BD Biosciences) mAb-
coated plates. On day 3, T lymphocytes were transduced with retro-
viral supernatants using retronectin-coated plates (Takara Bio, Shiga,
Japan). After removal from retronectin plates, T cells were expanded
in complete medium (45% RPMI 1640 and 45% Click’s medium
[Irvine Scientific], 10% FBS [Hyclone], 2 mM GlutaMAX,
100 U/mL penicillin, and 100 mg/mL streptomycin) with IL-7
(10 ng/mL; PeproTech) and IL-15 (5 ng/mL; PeproTech), changing
medium every 2–3 days. On days 12–14, cells were collected for
in vitro co-culture experiments.
Co-culture and ELISA
T cells (5 105) were co-cultured with T2 cells (5 105) in a 24-well
plate without the addition of exogenous cytokines. After 24 h, super-
natants were collected, and IFNg level was measured by using an
ELISA kit (R&D Systems) following the manufacturer’s instructions.
Each supernatant was measured in duplicate.
Flow Cytometry
The expression of SF2.CAR was detected using anti-Fab
antibody (Jackson ImmunoResearch Laboratories). Samples were
analyzed with BD FACSCanto II or BD FACSFortessa with
the BD Diva software (BD Biosciences); for each sample weMolecular Therapy: Oncolytics Vol. 15 December 2019 35
Molecular Therapy: Oncolyticsacquired a minimum of 10,000 events, and data were analyzed us-
ing FlowJo 10.
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